Market Research Report
Acute Myeloid Leukemia (AML) - The Changing Landscape of Treatment in AML, Executive Deck 2020
|Published by||Mellalta Meets LLP||Product code||953774|
|Published||Content info||235 Pages
Delivery time: 1-2 business days
|Acute Myeloid Leukemia (AML) - The Changing Landscape of Treatment in AML, Executive Deck 2020|
|Published: August 4, 2020||Content info: 235 Pages||
Acute myelogenous leukemia (AML) Disease Landscape provides comprehensive market intelligence with epidemiology, keen insight into current treatment paradigms, in-depth pipeline coverage ( ~ 470 unique industry-sponsored studies) and clinical trial landscape supported by detailed recent results (~ 96 trial's results) from ASH 2019, ASCO 2020 and EHA 2020. The drugs are further classified according to the class of therapies: antibody drug conjugates, bispecific antibodies, tri-specific and monoclonal antibodies, CAR-T therapies & T cells therapies, vaccines, small molecules and others.
Acute myelogenous leukemia (AML) is a cancer that starts in blood stem cells. Commonly known as acute myeloid leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute granulocytic leukemia or acute non-lymphocytic leukemia (ANLL). Once diagnosed, AML disease is described as untreated, in remission, or recurrent. The executive deck covers the AML overview, definition, diagnosis, percentage of patients based on mutation frequency, and treatment practice related unmet needs.
The main treatment for most types of AML is chemotherapy, along with a targeted therapy drug and followed by a stem cell transplant. In patients who are under 60 years old, induction chemotherapy for AML is given. The goal of induction therapy is to induce a remission, usually defined as less than 5% blast cells found in the bone marrow. Once remission is achieved, consolidation therapy is given. In this phase, chemotherapy is continued for 4-5 more cycles (4-6 months), generally with cytarabine alone, in higher doses.
The treatment of those over the age of 60 include recently approved new targeted therapies for AML-i.e., venetoclax, glasdegib, gemtuzumab, gemtuzumab, enasidenib, mitoxantrone, decitabine, azacitidine, midostaurin and clofarabine .